选择固体制剂是可行的基于甲磺酸艾氟替尼的化学性质及其与辅料的相容试验结

The choice of solid preparation is feasible based on the chemical properties of eftinib mesylate and its compatibility test results with excipients; <br>from the perspective of drug characteristics and compliance with clinical medication, oral solid preparations are preferred, and ordinary tablets are preferred. <br>Based on the above considerations, the target product profile is listed, and the attributes of the product that meet the patient's safety and effectiveness needs are briefly described in Table 3.2.P.2.2-1. <br>Table 3.2. P.2.2-1 Overview of the target product, eflutinib mesylate tablets, <br>based on aftinib (C28H31F3N8O2), accounting for 100% ± 10%

The selection of solid formulations is feasible based on the chemical properties of efluofonib and its compatibility with the auxiliary materials.<br>From the drug characteristics and clinical drug compliance considerations, the preferred oral solid preparation, and preferably ordinary tablets.<br>Based on the above considerations, the target product profile is listed, and the properties of the product that meet the patient's safety and effectiveness needs are outlined in Table 3.2.P.2.2-2-1.<br>Table 3.2.P.2.2-2-1 Overview of the target product, methasultine efluofinib tablets<br>In the form of efluoritinib (C28H31F3N8O2), 100% of the marked amount

It is feasible to select solid preparation based on the chemical properties of efetinib mesylate and the results of compatibility test with excipients;<br>In consideration of drug characteristics and compliance of clinical medication, oral solid preparation is preferred, and ordinary tablet is preferred.<br>Based on the above considerations, the profile of the target product is listed, and the attributes of the product to meet the safety and effectiveness needs of patients are summarized in table 3.2. P.2.2-1.<br>Table 3.2. P.2.2-1 overview of efetinib mesylate<br>Calculated by efetinib (c28h31f3n8o2), accounting for 100% ± 10% of the labeled amount<br>